Novel drugs and current therapeutic approaches in the treatment of heart failure

Drugs

Volumn 51, Issue 3, 1996, Pages 347-358

  Bonarjee, Vernon V S ^a   Dickstein, Kenneth ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ENDOTHELIN; ENKEPHALINASE INHIBITOR; FLOSEQUINAN; INOTROPIC AGENT; LOSARTAN; MILRINONE; PIMOBENDAN; PIPERANOMETOZINE; PROSTACYCLIN; VASODILATOR AGENT; XAMOTEROL;

DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; HEART FAILURE; HEART FUNCTION; HEMODYNAMICS; HUMAN; MORTALITY; REVIEW; SIDE EFFECT;

EID: 0029879413     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651030-00001     Document Type: Review

References (122)

1. SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
2. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28
3. Pfeffer M, Braunwald E, Moyé LA, et al., on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77
4. Conn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrite in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10
5. SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asympomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
6. Richardson A, Bayliss J, Sciven AJ, et al. Double blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987; 2: 709-11
7. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75
8. Cleland J, Dargie H, Ball S, et al. Effects of enalapril in heart failure: a double-blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54: 305-12
9. Creager MA, Faxon DP, Weiner DA, et al. Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril. Br Heart J 1985; 53: 431-5
10. Drexler H, Banhardt U, Meinertz T, et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. Circulation 1989; 79: 491-502
11. Kramer B, Topic N, Massie B. Acute and long-term effects of captopril in exercise cardiac performance and exercise capacity in congestive heart failure. Br J Clin Pharmacol 1982; 14: 143-51
12. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35
13. Kirlin PC, Grekin R, Das S, et al. Neurohumoral activation during exercise in congestive heart failure. Am J Med 1986; 81: 623-9
14. Wilson JR, Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. Am J Cardiol 1985; 6: 556-63
15. Mancini DM, Davis L, Wexler JP, et al. Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. J Am Coll Cardiol 1987; 10; 845-50
16. Corbalan R, Jalil J, Chamorro G, et al. Effects of captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure. Am J Cardiol 1990; 65: 644-9
17. Bonarjee VVS, Carstensen S, Caidahl K, et al. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol 1993; 72: 1004-9
18. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337: 872-6
19. Lamas G, Vaughan D, Parisi A, et al. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol 1989; 63: 1167-73
20. Dickstein K, Aarsland T. Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. J Am Coll Cardiol 1993; 22: 975-83
21. Smith TS, Braunwald E, Kelly RA. The management of heart failure. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders Co., 1992: 470-9
22. Coewley AJ, Stainer K, Wynne RD, et al. Symtomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986; 2: 770-2
23. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886-94
24. Kiyingi A, Field MJ, Paussel CC, et al. Metolazone and treatment of severe refractory congestive heart failure. Lancet 1990; 335: 29-31
25. Weber KT, Brilla CC. Pathologic hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65
26. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long term angiotensin II suppression. J Endocrinol 1981; 91: 457-65
27. van Vliet AA, Donker AJM, Nauta JJP, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin converting enzyme inhibitor. Am J Cardiol 1993; 71: 21A-8A
28. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980; 303: 1443-8
29. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Circulation 1989; 80: 65-77
30. Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoin and their combination in patients with severe heart failure. J Am Coll Cardiol 1989; 13: 134-42
31. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors: RADIANCE study. N Engl J Med 1993; 329: 1-7
32. Uretsky BF, Young JB, Shahidi FD, et al., on behalf of the PROVED investigative group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-62
33. Neuberg GW, Kukin ML, Penn J, et al. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991; 67: 63-6
34. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987; 9: 243-59
35. Streeten DHP, Andersen GH. Angiotensin receptor blocking drugs. In: Doyle AE, editor. Handbook of hypertension. Vol. 5: clinical pharmacology of antihypertensive drugs. New York/Amsterdam: Elsevier Science Publishing Co. Inc., 1984: 246-71
36. Fogari R, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992; 19: 670-3
37. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-90
38. Grinstead WC, Young JB. The myocardial renin-angiotensin system: existence, importance, and clinical implications. Am Heart J 1992; 123: 1039-45
39. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-42
40. Gottleib S, Dickstein K, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-9
41. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-7
42. Dickstein K, Chang PD, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-45
43. Simon S, Black H, Moser M, et al. Cough and ACE inhibitors. Arch Intern Med 1992; 152: 1698-700
44. Lindgren B, Anderson R. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough: a research review. Med Toxicol Adverse Drug Exper 1989; 4: 369-80
45. Kiowski W, Beerman J, Rickenbacher P, et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure: assessment by acute renin and converting enzyme inhibition. Circulation 1994; 90: 2748-56
46. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-50
47. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549-55
48. Baur LHB, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in pateints with coronary artery disease and heart failure. Br Heart J 1995; 73: 227-36
49. Dzau VJ. Molecular biology and heterogeneity of angiotensin II receptors. J Hypertens 1994; 12: S1-5
50. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality and chronic congestive heart failure: results of the Veterans Administration cooperative study. N Engl J Med 1986; 314: 1547-52
51. Fonarrow GC, Chemlimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine vs angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19: 842-50
52. Hirsch AT, Pinto YM, Schunkert H, et al. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990; 66: 22D-32D
53. Bussmann WD, Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary oedema. Am J Cardiol 1978; 41: 931-6
54. Leier CV, Bambach D, Thompson M, et al. Central and regional hemodynamic effects of intravenous isosorbid dinitrite, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 1981; 48: 1115-23
55. Packer M. The clinical significance of nitrate tolerance in patients with chronic heart failure. Eur Heart J 1989; 10 Suppl. A: 20-5
56. Kessler PD, Packer M. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J 1987; 113: 137-43
57. Yates DR. Pharmacology of flosequinan. Am Heart J 1991; 121: 974-83
58. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin and angiotensin-converting enzyme inhibitor: results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993; 88: 492-501
59. Packer M, Narahara KA, Elkayam U, et al. Double blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993; 22: 65-72
60. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure Preliminary results of the PROFILE study [abstract]. Circulation 1993; 88: 1-301
61. Sueta CA, Gheorghiade M, Adams KF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995; 75: 34A-43A
62. McKenna WJ, Swedberg K, Zannad F, et al. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: results of FIRST [abstract]. Eur Heart J 1994; 15: 36A
63. Haywood GA, Adams KF, Gheorghiade M, et al. Is there a role for epoprostenol in the management of heart failure? Am J Cardiol 1995; 75: 44A-50A
64. Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993; 22: 1223-7
65. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6
66. Kubo SH, Gollub S, Bourge R, et al. Beneficial effect of pimobendan on exercise tolerance and quality of life in patients with heart failure. Circulation 1992; 85: 942-9
67. Feldman AM, Bristow JD, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329: 149-55
68. Goldberg LI. Pharmacologic basis for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989; 14: S21-8
69. Leier CV, Heban PT, Huss P, et al. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: 466-72
70. Henwood JM, Todd PA. Ibopamine: a preliminary review of itsa pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988; 36: 11-31
71. Rajfer SI, Rossen JD, Douglas FL, et al. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation 1986; 73: 740-8
72. Rousseau MF, Ragioso J, van Eyll C, et al. Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovasc Pharmacol 1992; 19: 155-62
73. Cas LD, Metra M, Visioli O. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with heart failure. Am J Cardiol 1992; 70: 629-34
74. Girbes ARJ, Kalisvaart CJ, van Veldhuisen DJ, et al. Effect of ibopamine on renal haemodynamics in patients with severe congestive heart failure. Eur Heart J 1993; 14: 279-93
75. Cody RJ, Atas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362-74
76. Marguiles KB, Barclay PL, Burnett JC. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995; 91: 2036-42
77. Granger JP. Inhibitors of ANF metabolism: potential therapeutic agent in cardiovascular disease. Circulation 1990; 82: 313-5
78. Motwani JG, Lang CC, Allen MJ, et al. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther 1993; 54: 661-9
79. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1987; 41: 233-43
80. Gaffney TE, Braunwald E. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963; 34: 320-4
81. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790-804
82. Bristow MR. Pathophysiology and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993; 71: 12C-22C
83. Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol 1993; 71: 45C-53C
84. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-6
85. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154-61
86. Fischer ML, Gottleib SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23: 943-50
87. Swedberg K, Waagstein F, Hjalmarson A, et al. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet 1979; 1: 1374-6
88. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471-5
89. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-10
90. Gilbert EM, Anderson JL, Deitchman D, et al. Chronic β-blocker-vasodilator therapy improved cardiac function in idiopathic dilated cardiomyopathy: a double blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88; 223-9
91. Woodley SL, Gilbert EM, Anderson JL, et al. β-blockade with bucindolol in heart failure due to ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991 ; 84: 2426-41
92. Ruffolo Jr RR, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S82-8
93. DasGupta P, Broadhurst P, Raferty EB, et al. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66: 1118-23
94. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy. Circulation 1991; 84 Suppl. II: II-564
95. Olsen SL Gilbert EM, Renlund DG, et al. Carvedilol improves symptoms and left ventricular function in patients with congestive heart failure due to ischemic or idiopathic dilated cardiomyopathy [abstract]. J Am Coll Cardiol 1993; 21: 114A
96. Packer M, Bristow MR, Cohn J, et al. Effect of carvedilol on the survival of patients with chronic heart failure. Circulation 1995; 92 Suppl.: I-394
97. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart falure: a bridge too far. Circulation 1987; 75 Suppl. 5: V56-64
98. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-61
99. Packer M. Pathophysiologic mechanism underlying the adverse effects of calcium-channel blocking drugs in patients with chronic heart failure. Circulation 1989; 80 Suppl. 4: 59-67
100. Packer M, Nicod P, Khandheiria BR, et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild to moderate heart failure [abstract]. J Am Coll Cardiol 1991; 17: 274
101. Gradman AH. Hemodynamic efects of the vascular selective calcium antagonist felodipine in patients with impaired left ventricular function. Am Heart J 1992; 123: 273-8
102. Smith WB, DeAbate AC, Gollub SB, et al. Beneficial long-term hemodynamic and clinical effects of amlodipine in chronic heart failure: results of a multicenter, randomized, double-blind,placebo-controlled, dose-ranging study [abstract]. Circulation 1994; 90: I-603
103. O'Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE trial. Circulation 1995; 92 Suppl : I-143
104. Cohn J, Ziesche SM, Loss LE, et al. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT III. Circulation 1995; 92 Suppl.: I-143
105. Chakki CS, Gherghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985; 109: 497-504
106. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72: 681-5
107. Bigger Jr JT. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987; 75: 28-35
108. Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome from antiarrhythmic therapy: a dangerous imbalance in risk-benefit ratio. Am Heart J 1989; 118: 433-40
109. Ravid S, Podrid PJ, Lampert S, et al. Congestive heart failure induced by six newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14: 1326-30
110. Kaski JC, Girotti LA, Messuti H, et al. Long-term management of sustained recurrent symptomatic ventricular tachycardia with amiodarone. Circulation 1981; 64: 273-9
111. Cleland JGF, Dargie HJ, Findlay JN, et al. Clinical, haemodynamic and antiarrhythmic effect of long term treatment with amiodarone of patients in heart failure. Br Heart J 1987; 57: 436-45
112. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016-21
113. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82
114. Doval CH, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8
115. Singh SN, Fletcher RD, Fisher SG, et al., for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82
116. Freedman M, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991; 31: 1061-9
117. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 121: 158-71
118. Baker DW, Wright RF. Management of heart failure: IV. Anti-coagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994; 272: 1614-8
119. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. Circulation 1993; 87 Suppl. 6: VI-94-VI-101
120. McMurray J, Rankin A. Cardiology II: treatment of heart failure and atrial fibrillation and arrhythmias. BMJ 1994; 309: 1631-5
121. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-6
122. Teerlink JR, Löffler BM, Hess P, et al. Role of endothelin in the management of blood pressure in concious rats with chronic hearet failure: acute effects of the endothelin receptor antagonist Ro 47-0203 (Bosentan). Circulation 1994; 90: 2510-8